Evidence map›Paper›PMID 39193355›Full record

ArticleInternational journal of cancer medicine2024

What could be Improved at Melanoma Patients' Welfare Death? End of Life Perception of Caregivers.

Fernanda Cardoso Parreiras, Ana Paula Drummond-Lage, Marina Patrus Ananias de Souza Brandão, Laura Nogueira Silva, Lara Salvador Geo, Brenda Bhering Andrade, Andreia Cristina de Melo, Alberto Julius Alves Wainstein

Abstract read
In one paragraph

Article in International journal of cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Fernanda Cardoso ParreirasMedical Science Minas Gerais (CMMG), Belo Horizonte, Brazil.
Ana Paula Drummond-LageMedical Science Minas Gerais (CMMG), Belo Horizonte, Brazil.
Marina Patrus Ananias de Souza BrandãoMedical Science Minas Gerais (CMMG), Belo Horizonte, Brazil.
Laura Nogueira SilvaMedical Science Minas Gerais (CMMG), Belo Horizonte, Brazil.
Lara Salvador GeoMedical Science Minas Gerais (CMMG), Belo Horizonte, Brazil.
Brenda Bhering AndradeMedical Science Minas Gerais (CMMG), Belo Horizonte, Brazil.
Andreia Cristina de MeloNational Cancer Institute (INCA), Rio de Janeiro, Brazil.
Alberto Julius Alves WainsteinMedical Science Minas Gerais (CMMG), Belo Horizonte, Brazil.

Funding

Design of Oncolytic Adenovirus Conjugated with Novel Polymer for Cancer TreatmentR01CA177932 · NCI · UNIVERSITY OF UTAH · PI KIM, SUNG WAN · 2013 to 2017
$1.5M
NCI NIH HHS R01 CA177932
6 · The paper itself

Abstract

Despite enormous recent advances in stage IV melanoma treatment, it continues to have a significant mortality. Five-years survival is below 50% even when granted full access to effective therapeutic regimens. Considering the real world, mostly with low or medium-income countries like Brazil, where 75% of population depends on public health system receiving ineffective Dacarbazine chemotherapy, more than 95% of stage IV patients are dead before 5 years. Knowing the survival process of melanoma end-of-life time is imperative to help physicians to establish better symptoms control and improve the quality of death of these patients.

methodsRelative caregiver of melanoma end of life patients were invited to participate in a specific interview answering questions for the purpose of gathering information regarding symptoms and patients' complaints at the last 30 days, 7 days and at the day of death.

resultsAlthough melanoma has a highest propensity for brain dissemination, seizure and focal neurological deficits were not a major complaint. Most of dying melanoma symptoms are shared among other solid terminality tumor process and get worse from 30 days to 7 days, but the majority of symptoms kept unchanged from 7 days till time to death. Wound bleeding and bad odor were the only complaints that got worse during the whole terminality process and could be improved with better commitment of assistant team.

conclusionsalthough a strong effort is made to control brain metastasis, local and regional open wound metastasis represents a major remediable complaint that should receive more attention at end-of-life melanoma patients.

Indexed as

CaregiversEnd-of-lifeMelanomaPalliative careSymptomsTerminality

Identifiers

PMID39193355
PMCPMC11349044

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.